the National Comprehensive Cancer Network (NCCN) in the US have presented an updated version of their guidelines for the treatment of carcinoid tumors; octreotide was included for treatment of ...

The FDA has approved Cabometyx for some patients 12 years old and older with previously treated neuroendocrine tumors.

Jennifer Chan, MD, MPH, clinical director of the gastrointestinal cancer center and director of the program in carcinoid and neuroendocrine ... in recent decades. Treatments may include surgery ...

We decided to stop all antitumor treatment and to continue only with best supportive care. The patient died 31 months after the initial diagnosis. Patients with pulmonary carcinoid tumors can be ...

The global demand for advanced carcinoid tumor treatments is witnessing a profound acceleration ... This significant leap is attributed to rising incidences of carcinoid tumors, especially in the ...

"The characteristics of NET vary widely from patient to patient, and very few treatment options ... the Gastrointestinal Cancer Center and Director of the Program in Carcinoid and Neuroendocrine ...

Based on the phase 3 CABINET trial, the FDA approved Cabometyx for some patients with previously treated neuroendocrine ...